Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03616821 · ClinicalTrials.gov registry record · Phase 2
Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 242
- Enrollment target
NCT03616821 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 242 participants.
The verdict
NCT03616821, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 242 participants
- Enrollment target
Study Summary
The present study (D5272C00001/Legacy #3151-201-008) aims to evaluate the efficacy and safety of brazikumab in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy
Interventions
- DRUG Placebo
- DRUG Brazikumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2018-08-07 |
| Est. Completion | 2023-10-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03616821
The ClinicalTrials.gov registry entry for NCT03616821 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03616821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03616821 about?
NCT03616821 is a clinical study titled "Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis". The present study (D5272C00001/Legacy #3151-201-008) aims to evaluate the efficacy and safety of brazikumab in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on...
What is the current status of trial NCT03616821?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 242 participants. The study started on 2018-08-07. Estimated completion is 2023-10-23.
What interventions are being tested in trial NCT03616821?
The interventions under investigation include: Placebo (DRUG), Brazikumab (DRUG).
Who is sponsoring clinical trial NCT03616821?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.